Zoetis Inc. $ZTS Shares Sold by Wealth Enhancement Advisory Services LLC

Wealth Enhancement Advisory Services LLC lowered its holdings in Zoetis Inc. (NYSE:ZTS) by 33.2% in the fourth quarter, HoldingsChannel reports. The firm owned 71,590 shares of the company’s stock after selling 35,578 shares during the period. Wealth Enhancement Advisory Services LLC’s holdings in Zoetis were worth $9,260,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of ZTS. Halbert Hargrove Global Advisors LLC increased its holdings in Zoetis by 496.6% during the 3rd quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock worth $25,000 after purchasing an additional 144 shares during the last quarter. Global Wealth Strategies & Associates purchased a new position in shares of Zoetis during the 4th quarter valued at approximately $25,000. KERR FINANCIAL PLANNING Corp purchased a new position in shares of Zoetis during the 3rd quarter valued at approximately $31,000. Holos Integrated Wealth LLC acquired a new stake in shares of Zoetis during the fourth quarter worth approximately $32,000. Finally, Board of the Pension Protection Fund acquired a new stake in shares of Zoetis during the fourth quarter worth approximately $38,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Analysts Set New Price Targets

ZTS has been the topic of several recent analyst reports. The Goldman Sachs Group raised shares of Zoetis to a “buy” rating in a report on Monday, December 15th. Morgan Stanley set a $160.00 price objective on shares of Zoetis in a report on Thursday, December 18th. Leerink Partners reissued a “market perform” rating on shares of Zoetis in a research report on Tuesday, March 10th. Bank of America lifted their price target on Zoetis from $135.00 to $140.00 and gave the stock a “neutral” rating in a research note on Friday, February 13th. Finally, William Blair reissued an “outperform” rating on shares of Zoetis in a report on Monday, March 2nd. Six investment analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $152.91.

Zoetis Stock Down 2.7%

NYSE:ZTS opened at $113.48 on Friday. The company has a current ratio of 3.03, a quick ratio of 1.94 and a debt-to-equity ratio of 2.71. The stock has a 50 day moving average of $123.39 and a 200-day moving average of $129.31. The firm has a market capitalization of $47.90 billion, a PE ratio of 18.85, a price-to-earnings-growth ratio of 1.78 and a beta of 0.95. Zoetis Inc. has a 52 week low of $113.29 and a 52 week high of $172.23.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.40 by $0.08. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The business had revenue of $2.39 billion during the quarter, compared to analyst estimates of $2.36 billion. During the same quarter in the previous year, the firm posted $1.40 EPS. The business’s revenue for the quarter was up 3.0% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Analysts predict that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be given a $0.53 dividend. The ex-dividend date is Monday, April 20th. This represents a $2.12 annualized dividend and a yield of 1.9%. Zoetis’s dividend payout ratio is 35.22%.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.